“Development of LY2334737, an Oral Gemcitabine Prodrug for Continuous Administration. Perspectives for the Therapy of Mature T-Cell and NK-Cell Lymphomas”. Hematology Meeting Reports (formerly Haematologica Reports), vol. 3, no. 1, June 2009, https://doi.org/10.4081/hmr.v3i1.533.